NovAliX will employ its biophysical capabilities and medicinal chemistry potential in producing the lead candidates.
NovAliX president Stephan Jenn said, "This drug discovery collaboration with a leading Japanese pharmaceutical company also confirms the quality of our discovery platforms and its ability to deliver valuable lead candidates."
According to the deal, NovAliX is eligible for technology access fees in addition to research funding payments and milestone payments.